Artigos recentes: Nature Drug Discovery - 4 September 2009

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors doi:10.1038/nrd2871 This review considers factors such as pharmacogenomics and the tumour microenvironment that should be considered and applied in the development and use of new kinase inhibitors for treating cancer. Full Text

Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures doi:10.1038/nrc2717 This review considers the reasons why idiotype vaccines have thus far failed to achieve their main end points in randomized clinical trials and suggests how the clinical trials could be better designed. Full Text

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors doi:10.1038/nbt.1560 Aptamer-siRNA chimeras — optimized to enhance their silencing activity, enable systemic delivery, increase the circulating half-life and allow large-scale chemical synthesis — exhibited potent antitumour activity. Full Text

Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth doi:10.1038/nm.2018 A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (Vegfr-2) that encodes a secreted form of the protein inhibits developmental and reparative lymphangiogenesis by blocking Vegf-c function. Full Text